Skip to content
  • Home
  • How We Work
    • The Impact of Autophagy in Health and Disease
    • Biophagy’s Business Model
    • Biophagy’s Proprietary Drug Development
    • Cell Watchᵀᴹ
  • Business Development
  • Background & News
  • Team
  • Contact
Previous Next

Biophagy signs an option with STC.UNM to license and develop autophagy-related technologies and molecules created at the University of New Mexico

By jordan|2022-02-01T19:05:40+00:00February 1, 2022|2013-announcements|0 Comments

Share This Story, Choose Your Platform!

FacebookTwitterRedditLinkedInWhatsAppTelegramTumblrPinterestVkXingEmail

About the Author: jordan

Related Posts

  • Dr. Mary Ortner, Biophagy’s CEO, is elected vice president of the NM Biotechnology and Biomedical Association (NMBio), the BIO-affiliated NM trade association for bioscience in New Mexico.

    Dr. Mary Ortner, Biophagy’s CEO, is elected vice president of the NM Biotechnology and Biomedical Association (NMBio), the BIO-affiliated NM trade association for bioscience in New Mexico.

  • Dr. Steven Bradfute accepts a consulting position with Biophagy. He will advise the company and conduct assays in immunology and virology.

    Dr. Steven Bradfute accepts a consulting position with Biophagy. He will advise the company and conduct assays in immunology and virology.

  • Mary Ortner, PhD, MBA, accepts the position of president and CEO. She was previously SVP, business development and corporate alliances, at BioXcel Corporation.

    Mary Ortner, PhD, MBA, accepts the position of president and CEO. She was previously SVP, business development and corporate alliances, at BioXcel Corporation.

Leave A Comment Cancel reply

Copyright 2022 | All Rights Reserved | Website Design and Development by Ingenuity Software Labs
FacebookTwitterInstagramPinterest
Page load link
Go to Top